The clinical outcomes captured as secondary endpoints provide insights into the clinical relevance of anticoagulation reversal: in patients enrolled with acute bleeding (Group A), who could be assessed for time to cessation of bleeding, it took a median of 2.5 hours until the bleeding had stopped in patients enrolled with a need for urgent surgery or intervention (Group B), the required procedures could be initiated after a median of 1.6 hours. ![]() A single 5 g dose of idarucizumab was sufficient in 98 percent of patients. ![]() Reversal was independent of age, sex, kidney function or dabigatran concentration at baseline. Reversal became evident immediately after administration of idarucizumab and was maintained for 24 hours in most patients. The primary endpoint of RE-VERSE AD was reversal of the anticoagulant effect of Pradaxa within four hours as measured by diluted thrombin time (dTT) and ecarin clotting time (ECT), and was observed in 100 percent of patients (95 percent CI, 100-100). The findings were presented at the International Society on Thrombosis and Haemostasis (ISTH) 26th Biennial Congress in Berlin, Germany and simultaneously published in the New England Journal of Medicine. The reversal of the anticoagulant effect of Pradaxa allowed physicians to quickly initiate necessary emergency interventions. The effects were consistent both in patients requiring an urgent surgery or intervention, and in patients presenting with uncontrollable or life-threatening bleeding. as Praxbind®, was able to immediately reverse the anticoagulant effect of Pradaxa® (dabigatran etexilate mesylate) in patients in emergency situations. The study shows that idarucizumab, marketed in the U.S. RIDGEFIELD, Conn., J/PRNewswire/ - Boehringer Ingelheim today announced final results from RE-VERSE AD™.
0 Comments
Leave a Reply. |